24/7 Market News- Tevogen Bio Will Elaborate on the $1B+ Revenue Potential of its Pipeline Portfolio, Starting this Week
DENVER, Colo., Oct 14, 2024 (247marketnews.com)-Tevogen Bio (NASDAQ: TVGN) plans on sharing details of its $1B+ revenue potential, starting this week.
Ryan Saadi, MD, MPH, Tevogen Bio’s Founding CEO, stated, “In the current market reality, Tevogen Bio’s unique, faster, and cost-efficient drug development model has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. With over three decades of experience in the biopharma industry, Tevogen’s projected multi-billion-dollar revenue reassures me of the company’s strong business fundamentals and its bold, patient-centric drug development strategy, aimed at addressing some of the most pressing health conditions impacting large patient populations.”
Tevogen Bio’s pipeline includes TVGN 489, TVGN 920, TVGN 930, TVGN 960, and TVGN 601.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (TVGN)
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/05/25 03:00 PM
- MoBot’s Stock Market Highlights – 08/05/25 02:00 PM
- MoBot alert highlights: NASDAQ: ABEO, NASDAQ: WLDS, NASDAQ: AGMH, NASDAQ: TVGN, NASDAQ: BON (04/29/25 06:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/29/25 05:00 AM
- MoBot alert highlights: NASDAQ: WLDS, NASDAQ: TVGN, NASDAQ: AGMH, NASDAQ: BON, NASDAQ: LGMK (04/29/25 04:00 AM)